Laprixa™

OP-Zuid project STIM-00953: Further developing the Laprixa System.

Through the previous OP-Zuid project 01945, Corporis Medical was able to develop the Laprixa System in collaboration with its partners. Medanco B.V. of Veldhoven supported the development of the probe that performs the measurement on intestinal tissue, by injection molding the parts and assembling the probe in their clean room. AIM B.V. of Brunssum contributed to the development of the module that processes and presents the measurement data. The Laprixa technology has been tested in pre-clinical in-vivo models, which showed promising results.

Although the current Laprixa System is already quite impressive, Corporis Medical is constantly looking for ways to go one step further. With partners Medanco B.V. and AIM B.V., and with support from Stimulus through OP-Zuid project STIM-00953, the Laprixa System is being further developed with integration of oxygen saturation measurements. Considering that oxygen saturation is one of the most important indicators of wound healing capacity of anastomoses, this enhancement provides even more support to the surgeon in finding a suitable anastomosis site. This improvement requires an update of both the Laprixa probe and module. Furthermore, the production chain of the Laprixa System will be set up, with a clean room being installed at AIM B.V. Finally, verification and validation tests will be performed to ensure that the Laprixa System meets all requirements. As a project consortium, we aim to conclude this project with a market-ready product, which has been tested in both pre-clinical and clinical environments, with positive results.